Role of ofatumumab in treatment of chronic lymphocytic leukemia

about

A Novel Natural Product, KL-21, Inhibits Proliferation and Induces Apoptosis in Chronic Lymphocytic Leukemia Cells.

P2860

Q38840067-F9BF1B89-087D-4267-8E45-A37BBF727345

P2860

Role of ofatumumab in treatment of chronic lymphocytic leukemia

Item

http://www.wikidata.org/entity/Q35683837

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Role of ofatumumab in treatment of chronic lymphocytic leukemia

@ast

Role of ofatumumab in treatment of chronic lymphocytic leukemia

@en

type

Item

label

Role of ofatumumab in treatment of chronic lymphocytic leukemia

@ast

Role of ofatumumab in treatment of chronic lymphocytic leukemia

@en

prefLabel

Role of ofatumumab in treatment of chronic lymphocytic leukemia

@ast

Role of ofatumumab in treatment of chronic lymphocytic leukemia

@en

P1476

Role of ofatumumab in treatment of chronic lymphocytic leukemia

@en

P2093

Javier Pinilla-Ibarz

http://www.w3.org/2001/XMLSchema#string

Marays Veliz

http://www.w3.org/2001/XMLSchema#string

P2860

Genomic aberrations and survival in chronic lymphocytic leukemia

Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study

The biology of CD20 and its potential as a target for mAb therapy

The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20.

Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody.

Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.

Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment.

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.

Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas.

Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary struc

P304

71-77

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/JBM.S13063

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2011-05-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221789440

http://www.w3.org/2001/XMLSchema#string

P698

22287865

http://www.w3.org/2001/XMLSchema#string

P921

lymphocyte

P932

3262343

http://www.w3.org/2001/XMLSchema#string

Role of ofatumumab in treatment of chronic lymphocytic leukemia

about

P2860

P2860

Role of ofatumumab in treatment of chronic lymphocytic leukemia

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P5875

P698

P921

P932